Cobra enters into manufacturing agreement to produce SARS protein in CHO cells

February 28th 2008 Keele, UK: Cobra Biomanufacturing Plc (AIM: CBF), the international manufacturer of biopharmaceuticals, today announces that it has entered into a manufacturing development agreement with an undisclosed pharmaceutical company to produce a protein from the SARS virus in CHO (Chinese Hamster Ovary) cells under cGMP.

Cobra has earned a global reputation for the manufacture of therapeutic proteins and vaccines for clinical trials, including Phase III and pre-market material, at its cGMP manufacturing facilities in Keele and Oxford, UK.

Simon Saxby, Cobra Biomanufacturing’s Chief Operating Officer said: “We are delighted to work with the company, which is one of the top global players on the biopharmaceutical market. This agreement will leverage Cobra’s significant expertise in manufacturing recombinant proteins in compliance with worldwide cGMP requirements.”

The pharmaceutical company will carry out the upstream manufacturing of the SARS protein and ship media containing the protein of interest to Cobra. Cobra will perform the downstream work to isolate and purify the protein at its Oxford facility. The SARS protein will be used in Phase I clinical trials.

- ENDS -

For further information, please contact:

Cobra Biomanufacturing Plc
Tel: +44 (0) 1782 714 181
Simon Saxby, Chief Operating Officer

Buchanan Communications
Tel: +44 (0) 207 466 5000
Tim Anderson/Rebecca Skye Dietrich

College Hill Life Sciences
Tel: +44 (0) 20 7457 2020
Gemma Price/Adam Michael/Kathryn Robertson

Seymour Pierce (NOMAD & Broker)
Tel: +44 (0) 20 107 8000
Stuart Lane

About Cobra Biomanufacturing Plc:

Cobra Biomanufacturing Plc is a leading international contract manufacturer of biopharmaceuticals to the lifescience industry. Founded in 1992, Cobra provides innovative manufacturing solutions to the biopharmaceutical industry covering DNA, virus, cellular therapeutics and recombinant protein products.

Cobra has developed a range of unique, patented technologies, which underpin a successful revenue generating contract manufacturing business.

Cobra floated on the Alternative Investment Market of the London Stock Exchange in June 2002 raising £7 million and raised a further £5.2 million in May 2003 in order to further expand capacity in Oxford UK. Since floatation the Company has grown turnover from $6m to $20m providing expert manufacturing services across the world with over 80% of revenues currently originating from the US market.

www.cobrabio.com